Empowered Patient Podcast

Jens Hennecke, Chief Business Officer, SOTIO explains how this biotech company is developing the next generation of immunotherapies with a focus on a new compound called SO-C101 based on the cytokine IL-15, the key cytokine that activates T-cells and NK cells. In clinical trials, this drug, a modified IL-15 does not cause unwanted side effects like similar products to treat solid tumors and is a superagonist with a much better potency to activate memory T-cells, cytotoxic T-cells and NK cells. #SOTIO #immunotherapies #IL15 SOTIO.com Download the transcript here